CD4 and myeloid sarcoma: In fact, the immunometabolism of T cells is extremely relevant in the pathophysiology of MS, as evidenced by the fact that several of its therapeutic strategies modulate T cell metabolic features: Dimethyl Fumarate suppresses glycolysis; IFNγ decreases ATP levels, mitochondrial membrane potential and modulates OXPHOS; Teriflunomide limits T cell activation by blocking mitochondrial respiratory chain’s complex III; and Glatiramer Acetate promotes OXPHOS and represses glycolysis in CD4+ T cells (238).